BioSpace News Archive

Drug Development

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s 84th Scientific Sessions.

June 23, 2024
·
5 min read
BioMidwest

The American Diabetes Association Highlights Innovations in New Drug Therapies for Patients with Obesity

Findings from three studies showcase new data on the latest developments in drug therapy innovations to treat obesity including new insights on GLP-1 receptor agonists.

June 23, 2024
·
9 min read
Business

SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row

SPR Therapeutics has been honored as a Top Workplace for the third consecutive year by cleveland.com and The Plain Dealer Top Workplaces program.

June 23, 2024
·
4 min read
Deals

Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares

Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American depositary shares representing its ordinary shares.

June 23, 2024
·
1 min read